We are advancing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Our pipeline includes UCART19, our lead investigational product, in Phase 1 development for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
1 Servier holds ex-US commercial rights
UCART19, our lead investigational product, is an off-the shelf allogeneic CAR T therapy, or AlloCAR™, in clinical development for the treatment of CD19-expressing hematologic malignancies in partnership with Servier.
Servier is the sponsor of Phase 1 clinical trials in adult and pediatric relapsed or refractory acute lymphoblastic leukemia (ALL) clinical trials. ALL is a type of hematologic cancer that is associated with a poor long-term outcome for adults, adolescents and infants. Relapsed/refractory ALL is associated with particularly poor prognosis in adult patients and remains a serious treatment challenge. Phase 2 clinical trials of UCART19 are expected to start in 2019.